EULAR 2019年类风湿关节炎合成及生物改善病情抗风湿药管理建议更新
该更新基于2016年至2019年两次系统文献检索的新证据,由国际工作组投票形成5项总体原则和12条推荐,涵盖csDMARDs、糖皮质激素、bDMARDs及tsDMARDs的使用。推荐初始MTX联合GCs,3至6个月应答不足时按危险因素分层,存在不良预后因素者加用bDMARD或JAK抑制剂。
要点
- 初始治疗推荐MTX联合糖皮质激素。
- 3至6个月应答不足时按不良预后因素分层。
- 有不良预后因素者加用bDMARD或JAK抑制剂。
核心结论
- 更新版EULAR推荐在获益、安全、偏好和成本方面为RA管理提供共识。
研究设计与样本
- 国际工作组基于2016年上次更新至2019年的两次系统文献检索,评估DMARDs疗效与安全性证据,采用预设投票流程并独立投票同意度。
主要发现
- 工作组就5项总体原则和12条推荐达成一致,涉及csDMARDs、GCs、bDMARDs和tsDMARDs的使用。
- 推荐提供单药治疗、联合治疗、达标治疗策略及持续临床缓解后减量的指导。
- 推荐涉及b/tsDMARDs的成本和排序。
- 证据水平和同意度大多较高。
关键数值与推荐
- 初始推荐MTX联合GCs,若3至6个月内应答不足则按危险因素分层。
- 存在不良预后因素(自身抗体阳性、高疾病活动度、早期骨侵蚀或两种csDMARDs失败)时,在csDMARD基础上加用任何bDMARD或JAK抑制剂。
- 若上述治疗失败,推荐换用任何其他bDMARD(同类或不同类)或tsDMARD。
- 持续缓解时可减量DMARDs但不应停药。
临床怎么用
- 临床可按推荐以MTX联合GCs起始,3至6个月评估应答并依据不良预后因素决定加用bDMARD或JAK抑制剂。
- 持续缓解后考虑DMARDs减量但不宜完全停药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field. METHODS: An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic literature searches on efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) since the last update (2016) until 2019. A predefined voting process was applied, current levels of evidence and strengths of recommendation were assigned and participants ultimately voted independently on their level of agreement with each of the items. RESULTS: The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib). Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering on sustained clinical remission is provided. Cost and sequencing of b/tsDMARDs are addressed. Initially, MTX plus GCs and upon insufficient response to this therapy within 3 to 6 months, stratification according to risk factors is recommended. With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD or JAK inhibitor should be added to the csDMARD. If this fails, any other bDMARD (from another or the same class) or tsDMARD is recommended. On sustained remission, DMARDs may be tapered, but not be stopped. Levels of evidence and levels of agreement were mostly high. CONCLUSIONS: These updated EULAR recommendations provide consensus on the management of RA with respect to benefit, safety, preferences and cost.
引用
- Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020. PMID: 31969328. doi:10.1136/annrheumdis-2019-216655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。